Misonix Incorporated Adds 6 Spine Sales Agencies In The U.S.

FARMINGDALE, N.Y., Aug. 7, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has entered into new, multi-year agency agreements with six leading regional spine surgery sales organizations for the marketing of the Misonix® BoneScalpel Ultrasonic Bone Cutting System. The agreements are indicative of the Company’s commitment to capitalize on the growing clinical use of the BoneScalpel in advanced spine surgery procedures. Each agreement is performance based with each agency committing to certain levels of sales. Product training has been completed and open market sales have commenced.

Included in the sales line-up are upstate New York-based Premier Orthopedic Solutions, Las Vegas-based Trinity Medical, Gilbert Medical of Virginia, NKB Medical located in Birmingham, AL, Florida based Manatee Medical, and Excella Medical, which is located in southern California. Each of these organizations has a proven history of launching state-of-the-art spine products into their respective markets, including implantable spine hardware, biologics and sealants.

Bruce Tanner, Agency Principal for Premier Orthopedic Solutions, Inc., said, “We are excited to partner with Misonix. Their BoneScalpel Ultrasonic Bone Cutting System provides our surgeons with a safe, precise and efficient way to remove bone during delicate spine surgery procedures. Additionally, it allows us to represent a valuable, state-of-the-art technology to surgeons for whom we have not been able to offer a differentiating product in the past. Partnering with Misonix helps us to further enhance our reputation as premier sales consultants.”

The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps as represented by saws and drills. The BoneScalpel’s use in hospitals worldwide for numerous procedures in spine and skull-based surgery is on the rise.

“We are excited to have high-caliber agencies such as these join our growing family of market segment specific sales organizations in the United States; their presence demonstrates our commitment to capitalizing on large market opportunities like spine surgery. We are aware of their past records of successfully introducing new spine products to their markets,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “We are very pleased that they will bring their market presence and sales expertise to the clinical proliferation of BoneScalpel.”

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.